6533b851fe1ef96bd12a994b
RESEARCH PRODUCT
Rapid development of Epstein-Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient.
Christoph SchrammJörg F. SchlaakPeter R. Gallesubject
FoscarnetMaleEpstein-Barr Virus InfectionsHIV InfectionsDermatologymedicine.disease_causeAntiviral AgentsVirusHerpesviridaehemic and lymphatic diseasesMedicineHumansPharmacology (medical)Sidabiologybusiness.industryPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseasebiology.organism_classificationEpstein–Barr virusVirologyHodgkin DiseaseLymphomaInfectious DiseasesFoscarnet SodiumImmunologyViral diseasebusinessmedicine.drugFoscarnetdescription
Epidemiological features suggest a link between Hodgkin's disease (HD) and Epstein-Barr virus (EBV) infection1. Indeed, EBV genome and expression of latent antigens can be found in Reed-Sternberg cells. In the majority of cases HD in HIV patients seems to be EBV-associated. We report on a 51-year-old HIV-infected patient in whom EBV-positive HD of mixed cellularity rapidly developed within one month after cessation of treatment with intravenous foscarnet.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2000-09-21 | International journal of STDAIDS |